arrow
A

Annamaria Mascolo

link campus university
H指数:26
被引数:1,781

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Adverse event reporting patterns of selective serotonin reuptake inhibitors (SSRIs): disproportionality analysis using the European spontaneous reporting system

选择性血清素再摄取抑制剂(SSRIs)的不良事件报告模式:基于欧洲自发报告系统的比例失衡分析

2026-09-190
OAAI
Real-world safety comparison of liraglutide and semaglutide in weight management: Insights from European pharmacovigilance data

利拉鲁肽和司美格鲁肽在体重管理中的真实世界安全性比较:来自欧洲药物警戒数据的见解

2025-07-250
OA
Major Adverse Cardiovascular Events Related to JAK Inhibitors: A Disproportionality Analysis Using the WHO Global Individual Case Safety Database (APR, 10.1007/s40264-025-01535-8, 2025)

与JAK抑制剂相关的主要不良心血管事件:一项利用WHO全球个体病例安全数据库的不均衡性分析(APR, 10.1007/s40264-025-01535-8, 2025)

2025-04-220
OA
Retrospective Analysis of a Real-Life Use of Tixagevimab-Cilgavimab plus SARS-CoV-2 Antivirals for Treatment of COVID-19

对现实生活中使用tixagevimab-cilgavimab加SARS-CoV-2抗病毒药物治疗新型冠状病毒肺炎的回顾性分析

2023-10-200
OAAI
COVID-19 Vaccines and Atrial Fibrillation: Analysis of the Post-Marketing Pharmacovigilance European Database

新型冠状病毒肺炎疫苗与心房颤动: 上市后欧洲药物警戒数据库分析

2023-05-301
OAAI